InterventionsHumans
SAT-661 1. Hepatic and Cardiovascular Outcomes of Patients with Metabolic Dysfunction-Associated Steatotic-Liver Disease and Diabetes Mellitus Type 2 Treated with Glucagon-Like Peptide 1 Agonists
ENDO 2025 Abstract
The paper
Al Ashi S, Shah R, Iftikhar N et al.
ENDO 2025 Abstract · 22 Oct 2025 · CC BY-NC-ND
Presented at ENDO 2025
